• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

提供基因检测的投资优先级框架。

A framework for the prioritization of investment in the provision of genetic tests.

作者信息

Kroese Mark, Burton Hilary, Whittaker Joanne, Lakshman Rajalakshmi, Alberg Corinna

机构信息

PHG Foundation, Strangeways Research Laboratory, Cambridge, UK.

出版信息

Public Health Genomics. 2010;13(7-8):538-43. doi: 10.1159/000294278. Epub 2010 Mar 15.

DOI:10.1159/000294278
PMID:20224243
Abstract

BACKGROUND

The UK Genetic Testing Network (UKGTN) established a process for the evaluation of genetic tests for entry onto the National Health Service (NHS) Directory of Molecular Genetic Testing. The Network requested the development and piloting of a prioritization framework that could be used for the commissioning of genetic tests by the NHS.

METHODS

A selected working group developed and piloted a multi-criteria prioritization process using 10 genetic tests evaluated by the UKGTN.

RESULTS

The framework was able to rank the 10 genetic tests used in the pilot. The rankings were also consistent with the commissioning recommendations for these genetic tests by the UKGTN.

CONCLUSION

A set of criteria for the prioritization of genetic tests has been developed. The results from the pilot suggest that the methodology is valid and robust but requires considerable resources to implement. Further development of the process is needed before the framework could be used to influence commissioning decisions for clinical genetic services in the NHS.

摘要

背景

英国基因检测网络(UKGTN)建立了一个评估基因检测的流程,以纳入国家医疗服务体系(NHS)分子基因检测目录。该网络要求开发并试行一个优先级框架,用于NHS对基因检测的委托安排。

方法

一个选定的工作组使用UKGTN评估的10项基因检测开发并试行一个多标准优先级流程。

结果

该框架能够对试点中使用的10项基因检测进行排名。这些排名也与UKGTN对这些基因检测的委托安排建议一致。

结论

已制定了一套基因检测优先级标准。试点结果表明,该方法有效且稳健,但实施需要大量资源。在该框架可用于影响NHS临床基因服务的委托安排决策之前,还需要对该流程进行进一步开发。

相似文献

1
A framework for the prioritization of investment in the provision of genetic tests.提供基因检测的投资优先级框架。
Public Health Genomics. 2010;13(7-8):538-43. doi: 10.1159/000294278. Epub 2010 Mar 15.
2
How can genetic tests be evaluated for clinical use? Experience of the UK Genetic Testing Network.基因检测如何进行临床应用评估?英国基因检测网络的经验。
Eur J Hum Genet. 2007 Sep;15(9):917-21. doi: 10.1038/sj.ejhg.5201867. Epub 2007 May 30.
3
[Quality of genetic services--analysis of medical genetic expert opinions solicited by private health insurance companies].[基因检测服务质量——对私人健康保险公司征集的医学遗传学专家意见的分析]
Z Evid Fortbild Qual Gesundhwes. 2012;106(3):217-23. doi: 10.1016/j.zefq.2011.07.020. Epub 2012 Mar 24.
4
Competences, education and support for new roles in cancer genetics services: outcomes from the cancer genetics pilot projects.癌症遗传学服务新角色的能力、教育与支持:癌症遗传学试点项目的成果
Fam Cancer. 2007;6(2):171-80. doi: 10.1007/s10689-007-9127-y. Epub 2007 May 23.
5
Genetic testing services are to be regulated to protect UK patients.基因检测服务将受到监管,以保护英国患者。
BMJ. 2010 Aug 4;341:c4215. doi: 10.1136/bmj.c4215.
6
Orphan tests.孤儿检测
Camb Q Healthc Ethics. 1996 Spring;5(2):300-6. doi: 10.1017/s0963180100007076.
7
National evaluation of NHS genetics service investments: emerging issues from the cancer genetics pilots.英国国家医疗服务体系(NHS)遗传学服务投资的全国性评估:癌症遗传学试点项目中出现的新问题。
Fam Cancer. 2007;6(2):257-63. doi: 10.1007/s10689-007-9130-3. Epub 2007 May 23.
8
Newborn health screenings.新生儿健康筛查。
NCSL Legisbrief. 2012 Dec;20(47):1-2.
9
How can the evaluation of genetic tests be enhanced? Lessons learned from the ACCE framework and evaluating genetic tests in the United Kingdom.如何加强基因检测的评估?从ACCE框架及英国基因检测评估中汲取的经验教训。
Genet Med. 2005 Sep;7(7):495-500. doi: 10.1097/01.gim.0000179941.44494.73.
10
[Guideline of the Genetic Diagnosis Committee (GEKO) for requirements regarding the content of patient information in genetic studies for medical purposes in accordance with 23 Abs. 2 no. 3 GenDG].[遗传诊断委员会(GEKO)根据《基因诊断法》第23条第2款第3项对医学目的基因研究中患者信息内容要求的指南]
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2012 Aug;55(8):1071-5. doi: 10.1007/s00103-012-1521-4.

引用本文的文献

1
Organizational aspect in healthcare decision-making: a literature review.医疗保健决策中的组织因素:文献综述
J Mark Access Health Policy. 2020 Aug 31;8(1):1810905. doi: 10.1080/20016689.2020.1810905.
2
Healthcare System Priorities for Successful Integration of Genomics: An Australian Focus.基因组学成功整合的医疗保健系统优先事项:以澳大利亚为重点
Front Public Health. 2019 Mar 11;7:41. doi: 10.3389/fpubh.2019.00041. eCollection 2019.
3
Clinical impact of a targeted next-generation sequencing gene panel for autoinflammation and vasculitis.
用于自身炎症和血管炎的靶向新一代测序基因检测板的临床影响
PLoS One. 2017 Jul 27;12(7):e0181874. doi: 10.1371/journal.pone.0181874. eCollection 2017.
4
Assessing the value of healthcare interventions using multi-criteria decision analysis: a review of the literature.使用多标准决策分析评估医疗保健干预措施的价值:文献综述
Pharmacoeconomics. 2014 Apr;32(4):345-65. doi: 10.1007/s40273-014-0135-0.
5
Criteria for fairly allocating scarce health-care resources to genetic tests: which matter most?公平分配稀缺医疗资源用于基因检测的标准:哪些因素最为重要?
Eur J Hum Genet. 2014 Jan;22(1):25-31. doi: 10.1038/ejhg.2013.172. Epub 2013 Aug 7.
6
The promises of genomic screening: building a governance infrastructure. Special issue: genetics and democracy.基因组筛查的前景:构建治理基础设施。特刊:遗传学与民主。
J Community Genet. 2012 Apr;3(2):73-7. doi: 10.1007/s12687-011-0056-y. Epub 2011 Jul 7.